Blocking JNK (c-Jun N-terminal kinase)/AP-1 inhibits AXL transcription and attenuates drug resistance to PI3Kα therapy in esophagus cancer and head and neck squamous cell carcinoma [35]. This evidence concerns the gene AXL and esophageal cancer.